CN-121987662-A - Application of hydrogen-rich water in preparation of medicines for treating Duchenne muscular dystrophy

Abstract

The invention discloses application of hydrogen-rich water in preparation of medicines for treating Duchenne type muscular dystrophy, and in particular relates to the technical field of medicines, wherein a random control experiment is adopted, homologous C57 mice are used as a normal control group, mdx mice are randomly divided into a model group and a hydrogen-rich water group, movement capacity is evaluated by an extremity grasping force test and a stick rotation test, an enzyme-linked immunosorbent assay is used for detecting mouse creatine kinase, hematoxylin-eosin, NADH-tetrazole reductase, improved Gomori trichromatic staining, cytochrome C oxidase, succinic dehydrogenase, SDH-COX combined staining are used for observing pathological changes of skeletal muscle tissues, immunohistochemistry, fluorescent dystrophin protein expression conditions and the like, and the hydrogen-rich water is disclosed to have higher application prospect and economic value on muscle injury conditions of Duchenne type muscular dystrophy model mice through a mitochondrial protection mechanism.

Inventors

• YU XUEN
• ZHANG JIE
• SHAO JIE
• GAO TIAN
• SHI YONGGUANG
• Sha Congbo
• FU XIAOMING
• SONG BIN
• ZHANG LIANGLIANG

Assignees

• 安徽中医药大学

Dates

Publication Date

20260508

Application Date

20260317

Claims (10)

1. 1. Use of hydrogen-enriched water in the preparation of a medicament for the treatment of Duchenne muscular dystrophy.
2. 2. The use according to claim 1, wherein the hydrogen concentration in the hydrogen-rich water is 1-3 ppm.
3. 3. The use according to claim 1, wherein the hydrogen enriched water acts to ameliorate skeletal muscle injury caused by Duchenne muscular dystrophy by a mitochondrial protection mechanism.
4. 4. The use according to claim 1, wherein the medicament is an oral liquid or an injection, wherein the medicament can be prepared by adding pharmaceutically acceptable auxiliary materials into hydrogen-enriched water, or by mixing hydrogen-enriched water with other medicaments having a preventive or therapeutic effect on Duchenne muscular dystrophy, and adding or not adding pharmaceutically acceptable auxiliary materials.
5. 5. Use of hydrogen enriched water in a mechanistic study experiment for improving skeletal muscle function in Duchenne muscular dystrophy mice.
6. 6. The use according to claim 5, wherein the skeletal muscle function is grip, rotarod.
7. 7. Use of hydrogen enriched water in research experiments for influencing serum CK level changes in Duchenne muscular dystrophy mice.
8. 8. Use of hydrogen-enriched water in a mechanistic study experiment for alleviating skeletal muscle pathological lesions in Duchenne muscular dystrophy mice.
9. 9. Use of hydrogen enriched water in a mechanism study experiment for enhancing skeletal muscle dystrophin protein expression in Duchenne muscular dystrophy mice.
10. 10. Use of hydrogen enriched water in a mechanistic study experiment for restoring skeletal muscle ultrastructural changes in Duchenne muscular dystrophy mice.

Description

Application of hydrogen-rich water in preparation of medicines for treating Duchenne muscular dystrophy Technical Field The invention belongs to the technical field of medicines, and particularly relates to application of hydrogen-rich water in preparation of a medicine for treating Duchenne muscular dystrophy. Background Duchenne muscular dystrophy (Duchenne muscular dystrophy, DMD) is an X-chromosome linked recessive inherited neuromuscular disorder, caused by mutations in the dystrophin (dystrophin) gene, with a global incidence of about 1/3500-1/5000, mainly male. DMD patients generally begin to develop disease in the age of 3-5 years, with early onset of abnormal increases in creatine kinase (CREATINE KINASE, CK), loss of dystrophin leading to decreased muscle cell membrane stability, and ultimately progressive myofiber necrosis, fat and fiber tissue replacement, and loss of muscle function. Mitochondrial dysfunction is one of the earliest seen cellular changes in DMD muscle fibers, occurring prior to onset of muscle disease, significant swelling of mitochondria with cristae destruction was observed in the ultrastructure of mdx mice and progressed with the severity of the disease. There is no cure for DMD, and although gene therapy and hormone therapy achieve a certain effect in delaying disease progression, long-term side effects and limitations in therapeutic effects are still in need of solving. Therefore, it is of great importance to explore novel safe and effective therapeutic strategies. In recent years, hydrogen-rich water (HRW) has been considered to have effects of modulating antioxidant enzymes, reducing inflammation, preventing mitochondrial dysfunction, and modulating cell signaling pathways, etc., due to its selective antioxidant properties. However, no report has been made as to whether hydrogen-rich water has an effect of treating DMD and how specific mechanism is. Disclosure of Invention The technical problem to be solved by the invention is how to propose a new application of hydrogen-enriched water, in particular to prevent and treat Duchenne Muscular Dystrophy (DMD). The invention solves the technical problems by the following technical means: The invention provides application of hydrogen-rich water in preparing a medicament for treating Duchenne Muscular Dystrophy (DMD). Preferably, the concentration of hydrogen in the hydrogen-rich water is 1-3 ppm, and the hydrogen-rich water is dissolved in purified water, and is prepared into solutions with different hydrogen concentrations according to the requirements when in use. Further preferably 1.5 ppm. Preferably, the hydrogen-enriched water ameliorates skeletal muscle injury caused by Duchenne Muscular Dystrophy (DMD) by a mitochondrial protection mechanism. Further preferably, the hydrogen-enriched water indirectly inhibits NF- κB mediated inflammatory response by activating Nrf2/ARE signal pathway, up-regulating endogenous antioxidant enzyme expression, thereby effectively maintaining mitochondrial structure and functional integrity, and improving skeletal muscle injury caused by Duchenne Muscular Dystrophy (DMD). Preferably, the medicine can be added with pharmaceutically acceptable auxiliary materials in the hydrogen-rich water, or the hydrogen-rich water is mixed with other medicines with the effect of preventing or treating Duchenne muscular dystrophy, and the pharmaceutically acceptable auxiliary materials are added or not added. Preferably, the medicament is an oral liquid or an injection. The invention also provides application of the hydrogen-rich water in a mechanism research experiment for improving skeletal muscle function of Duchenne Muscular Dystrophy (DMD) mice. Further preferably, the skeletal muscle function includes, but is not limited to, grip, rotation bar. The invention also provides application of the hydrogen-rich water in research experiments for influencing serum CK level change of Duchenne Muscular Dystrophy (DMD) mice. The invention also provides application of the hydrogen-rich water in a mechanism research experiment for alleviating skeletal muscle pathological injury of Duchenne Muscular Dystrophy (DMD) mice. The invention also provides application of the hydrogen-rich water in a mechanism research experiment for enhancing the expression of Duchenne Muscular Dystrophy (DMD) mouse skeletal muscle dystrophin protein. The invention also provides application of the hydrogen-rich water in a mechanism research experiment for recovering the skeletal muscle ultrastructural change of the Duchenne Muscular Dystrophy (DMD) mice. The invention has the beneficial effects that: 1. The invention provides a new application of hydrogen-enriched water in preparing medicines for treating Duchenne Muscular Dystrophy (DMD), and proves the improvement effect of hydrogen-enriched water on skeletal muscle of mdx mice on the analysis results of mouse behaviours, serum enzymology, skeletal muscle histopathological morphology and u